Table 4.

Clinical, microbiological, and global response rates at various pre-defined efficacy timepoints throughout the study in the MITT population

	MITT population
Timepoint	Clinical response, % [n / N] (95% CI)	Microbiological response, % [n / N] (95% CI)	Global response, % [n / N] (95% CI)
End of intravenous treatment	81.0 [34/42]	85.7 [36/42]	78.6 [33/42]
	(65.9–91.4)	(71.5–94.6)	(63.2–89.7)
2 weeks after EOT	83.9 [26/31]	80.6 [25/31]	75.0 [24/32]
	(66.3–94.5)	(62.5–92.5)	(56.6–88.5)
6 weeks after EOT	56.7 [17/30]	56.7 [17/30]	54.8 [17/31]
	(37.4–74.5)	(37.4–74.5)	(36.0–72.7)
12 weeks after baseline	54.8 [17/31]	51.6 [16/31]	50.0 [16/32]
	(36.0–72.7)	(33.1–69.8)	(31.9–68.1)

Abbreviations used: CI, confidence interval; EOT, end of all treatment; MITT, modified intent-to-treat.